latest news releases from the newsroom
Update on OMX's 24 Percent Ownership in EDX London
STOCKHOLM, Sweden, Nov. 3, 2005 (PRIMEZONE) -- EDX London Ltd, jointly owned by London Stock Exchange and OMX (76 and 24 percent respectively), offers trading and clearing in Scandinavian equity derivatives as well as over-the-counter equity derivatives services in London. During the period April-September 2005, EDX London traded a total of 10.1 million (9.2) contracts, mainly relating to Scandinavian equity derivatives. Although development of services for the over-the-counter equity derivatives market continued during the period, this service does not justify further investment. It is therefore today being announced in London Stock Exchange's Interim Report for April-September that an exceptional impairment loss has been recognized in EDX London. The total impairment in EDX London amounts of GBP 22 m, principally in respect of the impairment of goodwill. OMX owns 24 percent of EDX London, which is treated in OMX' accounts as an associated company.
Novartis Announces Leadership of New Vaccines and Diagnostics Business
BASEL, Switzerland, Nov. 3, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has designated Dr. Joerg Reinhardt, currently Global Head of Pharma Development, to become CEO of a new Novartis division that will combine Chiron Corporation's (Nasdaq:CHIR) vaccines and diagnostics business, pending regulatory and shareholder approvals. In this new role, Dr. Reinhardt will report directly to Dr. Daniel Vasella, the Chairman and CEO of Novartis.
Pharming Group N.V.
Pharming Announces Results for First Nine Months 2005
LEIDEN, Netherlands, Nov. 3, 2005 (PRIMEZONE) -- Highlights: upcoming product filings, licensing progress and pipeline expansion. Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today its financial results for the third quarter of 2005 and for the first nine months ended September 30, 2005. The Company highlighted upcoming product filings for recombinant human C1 inhibitor (rhC1INH) and its human lactoferrin product (rhLF), licensing progress and its pipeline expansion.
Microsemi to Acquire Advanced Power Technology, Inc.
IRVINE, Calif. and BEND, Ore., Nov. 2, 2005 (PRIMEZONE) -- Microsemi Corporation ("Microsemi") (Nasdaq:MSCC) and Advanced Power Technology, Inc. ("APT") (Nasdaq:APTI) today announced the signing of a definitive agreement for Microsemi to acquire APT. With this acquisition, Microsemi, a world leader in the design and manufacture of high performance analog solutions and high reliability semiconductor solutions, expands its portfolio of analog mixed signal offering in the RF marketplace and also its high reliability offering in the defense/aerospace and medical marketplace.
Cubic Energy, Inc.
Cubic Energy, Inc. Initiates Re-Completions
DALLAS, Nov. 2, 2005 (PRIMEZONE) -- Cubic Energy, Inc. (OTCBB:QBIK) announced today that it will initiate additional completion work for behind pipe reserves in the Moseley 25 No.1 well and the Moseley 26 No.1 well in the Bethany Longstreet Field, DeSoto Parish, Louisiana.